Edition:
United States

Key Developments: CTi Biopharma Corp (CTIC.O)

CTIC.O on Consolidated Issue listed on NASDAQ Capital Market

0.45USD
24 May 2016
Change (% chg)

$-0.00 (-0.51%)
Prev Close
$0.45
Open
$0.45
Day's High
$0.46
Day's Low
$0.43
Volume
972,360
Avg. Vol
1,901,700
52-wk High
$2.46
52-wk Low
$0.25

Latest Key Developments (Source: Significant Developments)

CTI Biopharma Q1 earnings per share $0.01
Tuesday, 10 May 2016 04:58pm EDT 

CTI Biopharma Corp : CTI Biopharma reports first quarter 2016 financial results . Q1 earnings per share $0.01 .Q1 revenue $36.5 million versus $2.7 million.  Full Article

CTI BioPharma Corp prices underwritten public offering of $55 mln of convertible preferred Stock
Friday, 4 Dec 2015 11:15am EST 

CTI BioPharma Corp:Says pricing of an underwritten public offering of 55,000 shares of its Series N-2 Preferred Stock, offered at a price to the public of $1,000 per share of Series N-2 Preferred Stock.Says each share of Series N-2 Preferred Stock is convertible at option of the holder, at any time subject to certain limitations, into shares of our common stock at a conversion price of $1.10 per share of common stock, for a total of approximately 50,000,000 shares of common stock.  Full Article

CTI BioPharma Corp announces proposed public offering of convertible preferred stock
Thursday, 3 Dec 2015 04:31pm EST 

CTI BioPharma Corp:Announces proposed public offering of convertible preferred stock.Each share of series n-2 preferred stock will have a stated value of $1,000 per share.To use net proceeds for launch of pacritinib in U.S., to conduct additional research for application of pacritinib.To also use net proceeds to advance commercialization of pixuvri, for development of tosedostat in registration-directed trials.  Full Article

CTI BioPharma Corp lowers FY 2015 revenue guidance; reaffirms FY 2015 Non-GAAP operating loss guidance
Thursday, 5 Nov 2015 04:01pm EST 

CTI BioPharma Corp:Expects total revenues for FY 2015 will be approximately $30 million to $45 million.Expects Non-GAAP operating loss for FY 2015 will be approximately $75 million to $85 million.FY 2015 revenue of $51 million and EBIT of $(77) million - Thomson Reuters I/B/E/S.  Full Article

CTI BioPharma Corp prices underwritten public offering of $50 mln of convertible preferred stock
Tuesday, 27 Oct 2015 09:10am EDT 

CTI BioPharma Corp:Prices underwritten public offering of $50 million of convertible preferred stock.Says public offering of 50,000 shares of series n-1 preferred stock, at $1,000 per share of series n-1 preferred stock.To use net proceeds for commercial launch of pacritinib in u.s,conduct research for application of pacritinib outside of myelofibrosis.To use net proceeds to advance commercialization of pixuvri,support the development of tosedostat in registration-directed trials.  Full Article

CTI BioPharma Corp Announces Proposed Public Offering of Convertible Preferred Stock
Monday, 26 Oct 2015 04:33pm EDT 

CTI BioPharma Corp:Intends to offer and sell shares of its Series N-1 Preferred Stock in an underwritten public offering.Each share of Series N-1 Preferred Stock will have a stated value of $1,000 per share and will be convertible at the option of the holder, at any time after issuance, into shares of common stock prior to the automatic conversion of such shares in certain circumstances.CTI plans to use the net proceeds from this Offering to support the commercial launch of pacritinib in the U.S. for patients with myelofibrosis.Piper Jaffray & Co. is acting as sole book-running manager for the Offering. Ladenburg Thalmann & Co. Inc. is acting as lead manager for the Offering.  Full Article

CTI BioPharma Corp announces $15.7 mln registered direct offering
Thursday, 24 Sep 2015 04:30pm EDT 

CTI BioPharma Corp:Entered into an agreement with institutional investors to purchase 10 mln shares of the Company's common stock.Gross proceeds to the Company of about $15.7 mln at a purchase price per share of $1.57 equal to the consolidated closing bid price on The NASDAQ Global MarketSMon Sept. 23.Net proceeds from the Offering, after deducting estimated offering expenses, will be about $15.1 mln.  Full Article

CTI BioPharma to submit NDA for pacritinib in Q4 based primarily on data from single pivotal persist-1 trial
Wednesday, 23 Sep 2015 09:01am EDT 

CTI BioPharma Corp:Announced its plan to submit a new drug application (NDA) to the U.S. Food and Drug Administration following a productive pre-NDA meeting for pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R.Expects to submit the NDA in the fourth quarter of 2015.Decision follows pre-nda meeting with FDA to request accelerated approval for patients with myelofibrosis and low platelet counts.Says accelerated approval to be requested based on single trial, potentially reducing time to market.  Full Article

CTI BioPharma Corp reaffirms FY 2015 guidance
Thursday, 6 Aug 2015 04:01pm EDT 

CTI BioPharma Corp:Expects FY 2015 total revenues will be about $50 to $55 million.Expects FY 2015 non-GAAP operating loss will be about $75 to $85 mln.FY 2015 revenue of $54 mln and EBIT of $(64.20) mln - Thomson Reuters I/B/E/S.  Full Article

CTI BioPharma Corp says Pacritinib phase 3 study shows positive results in patient reported outcomes measuring quality of life in patients with myelofibrosis
Friday, 12 Jun 2015 03:30am EDT 

CTI BioPharma Corp and Baxter International's BioScience business:Says new patient-reported outcome (PRO) data for pacritinib - an investigational oral multikinase inhibitor with specificity for JAK2 and FLT3 - from the Phase 3 PERSIST-1 study.As recently reported at American Society of Clinical Oncology annual meeting, results show significant reduction in Total Symptom Score , and in each individual common disease-related symptom, from baseline to week 24, in patients treated with pacritinib compared to best available therapy.As previously reported, PERSIST-1 trial met its primary endpoint of spleen volume reduction of 35 pct or greater from baseline to week 24 as measured by MRI/CT scan.  Full Article

BRIEF-CTI Biopharma Q1 earnings per share $0.01

* Q1 revenue $36.5 million versus $2.7 million Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)